1. Home
  2. VKTX vs NCNO Comparison

VKTX vs NCNO Comparison

Compare VKTX & NCNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • NCNO
  • Stock Information
  • Founded
  • VKTX 2012
  • NCNO 2011
  • Country
  • VKTX United States
  • NCNO United States
  • Employees
  • VKTX N/A
  • NCNO N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • NCNO Computer Software: Prepackaged Software
  • Sector
  • VKTX Health Care
  • NCNO Technology
  • Exchange
  • VKTX Nasdaq
  • NCNO Nasdaq
  • Market Cap
  • VKTX 2.8B
  • NCNO 2.7B
  • IPO Year
  • VKTX 2015
  • NCNO 2020
  • Fundamental
  • Price
  • VKTX $27.55
  • NCNO $24.03
  • Analyst Decision
  • VKTX Buy
  • NCNO Buy
  • Analyst Count
  • VKTX 12
  • NCNO 15
  • Target Price
  • VKTX $84.00
  • NCNO $28.93
  • AVG Volume (30 Days)
  • VKTX 4.3M
  • NCNO 1.8M
  • Earning Date
  • VKTX 04-23-2025
  • NCNO 05-28-2025
  • Dividend Yield
  • VKTX N/A
  • NCNO N/A
  • EPS Growth
  • VKTX N/A
  • NCNO N/A
  • EPS
  • VKTX N/A
  • NCNO N/A
  • Revenue
  • VKTX N/A
  • NCNO $540,657,000.00
  • Revenue This Year
  • VKTX N/A
  • NCNO $9.25
  • Revenue Next Year
  • VKTX N/A
  • NCNO $8.11
  • P/E Ratio
  • VKTX N/A
  • NCNO N/A
  • Revenue Growth
  • VKTX N/A
  • NCNO 13.45
  • 52 Week Low
  • VKTX $18.92
  • NCNO $18.75
  • 52 Week High
  • VKTX $81.81
  • NCNO $43.20
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 53.68
  • NCNO 50.24
  • Support Level
  • VKTX $26.37
  • NCNO $21.73
  • Resistance Level
  • VKTX $30.28
  • NCNO $23.64
  • Average True Range (ATR)
  • VKTX 1.65
  • NCNO 0.77
  • MACD
  • VKTX 0.27
  • NCNO 0.30
  • Stochastic Oscillator
  • VKTX 56.53
  • NCNO 92.18

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About NCNO nCino Inc.

Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.

Share on Social Networks: